Stocklytics Platform
Asset logo for symbol MRNS
Marinus Pharmaceuticals
MRNS63
$0.23arrow_drop_up0.20%$0.00
Penny Stock
Asset logo for symbol MRNS
MRNS63

$0.23

arrow_drop_up0.20%

Performance History

Chart placeholder
Key Stats
Open$0.24
Prev. Close$0.23
EPS-2.47
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$12.69M
PE Ratio-
LOWHIGH
Day Range0.23
0.24
52 Week Range0.23
11.26
Ratios
Revenue-
EPS-2.47

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

About Marinus Pharmaceuticals (MRNS)

Marinus Pharmaceuticals Inc (MRNS) is a biopharmaceutical company that focuses on the development and commercialization of innovative therapeutics to treat epilepsy and other neurological disorders. The company's lead product candidate is ganaxolone, a selective, synthetic neurosteroid, which is being investigated for the treatment of various types of epilepsy, including refractory status epilepticus (RSE) and postpartum depression (PPD).
Ganaxolone has shown promising results in clinical trials, demonstrating its potential to reduce seizure activity and improve seizure control in patients with epilepsy. RSE is a life-threatening condition characterized by prolonged seizures that do not respond to initial treatment, while PPD is a mood disorder that can occur after childbirth.
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Scott N. Braunstein M.D.
Headquarters
Radnor
Employees
151
Exchange
NASDAQ
add Marinus Pharmaceuticals  to watchlist

Keep an eye on Marinus Pharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is Marinus Pharmaceuticals 's (MRNS) price per share?

The current price per share for Marinus Pharmaceuticals (MRNS) is $0.23. The stock has seen a price change of $0 recently, indicating a 0.21% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for Marinus Pharmaceuticals (MRNS)?

For Marinus Pharmaceuticals (MRNS), the 52-week high is $11.26, which is 4.8K% from the current price. The 52-week low is $0.23, the current price is -0.43% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is Marinus Pharmaceuticals (MRNS) a growth stock?

Marinus Pharmaceuticals (MRNS) has shown an average price growth of -4.38% over the past three years. It has received a score of 44 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Marinus Pharmaceuticals as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is Marinus Pharmaceuticals (MRNS) stock price performance year to date (YTD)?

As of the latest data, Marinus Pharmaceuticals (MRNS) has a year-to-date price change of -97.79%. Over the past month, the stock has experienced a price change of -28.64%. Over the last three months, the change has been -85.89%. Over the past six months, the figure is -82.71%. Looking at a longer horizon, the five-year price change stands at -97.53%.
help

Is Marinus Pharmaceuticals (MRNS) a profitable company?

Marinus Pharmaceuticals (MRNS) has a net income of -$141.4M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 93.76% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -375.94% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , with a revenue growth rate of 21.63%, providing insight into the company's sales performance and growth. The gross profit is $29.06M. Operating income is noted at -$131.48M. Furthermore, the EBITDA is -$128.66M.
help

What is the market capitalization of Marinus Pharmaceuticals (MRNS)?

Marinus Pharmaceuticals (MRNS) has a market capitalization of $12.69M. The average daily trading volume is 0.24, indicating the stock's liquidity and investor engagement.

Take Your Investments to a Whole New Level